UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3145961 (State or Other Jurisdiction of In ...

EXHIBIT 99.1 Anika Reports First Quarter 2024 Financial Results Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million, up over 75% at the midpoint BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its first quarter end ...

BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has appointed Steve Griffin as the Company's Executive Vice President, Chief Financial Officer ("CFO") and Treasurer, effective June 3, 2024. He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the company. Mr. Levitz will remain with the Company through December 31, 2024, to ensure a s ...

公司信息 - Anika Therapeutics, Inc.计划在2024年5月8日收盘后发布第一季度财务结果，并在当天下午5:30举行投资者电话会议[1] - Anika Therapeutics, Inc.是一家全球关节保护公司，致力于早期干预骨科领域，专注于关节炎疼痛管理、再生解决方案、运动医学和关节表面解决方案等领域[3] - ANIKA、ANIKA THERAPEUTICS和Anika标志是Anika Therapeutics, Inc.的注册商标[4] 电话会议信息 - 可通过拨打1-888-886-7786（国内免费）或1-416-764-8658（国际长途）并提供会议ID号1665626来参加电话会议[2]

BEDFORD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024. Anika will host a virtual presentation with Q&A starting at 2:15pm ET. Webcast of the presentation and Q&A will be available in the Investor Relations section of Anika's website, www.anika.com. An archive of the presen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3145961 (State or Other Jurisdiction ...

财务数据和关键指标变化 - 2023年全年收入为1.667亿美元,同比增长7%,超出公司最新指引 [46] - OA疼痛管理业务2023年全年收入为1.019亿美元,同比增长11%,超出公司指引 [47] - 关节修复与保护业务2023年全年收入为5,490万美元,同比增长9%,符合公司指引 [48] - 非骨科业务2023年全年收入为990万美元,同比下降29% [48] - 2023年全年调整后毛利率为66%,与上年持平,符合公司指引 [49] - 2023年全年调整后EBITDA利润率为9%,超出公司指引6%-8% [49] 各条业务线数据和关键指标变化 - OA疼痛管理业务: - 2023年第四季度收入增长12%,全年增长11%,主要得益于Monovisc在全球的强劲增长和Cingal在美国以外市场的持续两位数增长 [11][47] - 关节修复与保护业务: - 2023年第四季度收入增长7%,全年增长9%,新产品如X-Twist和RevoMotion带动增长,但被成熟产品销售下降所抵消 [20][34] - 非骨科业务: - 2023年第四季度收入下降8%,主要受到订单时间性影响和宠物业务高基数影响 [35] 各个市场数据和关键指标变化 - OA疼痛管理业务: - 国际市场2023年全年收入增长12%,主要得益于Cingal和Monovisc的两位数增长 [47] - 美国市场2023年全年收入增长10%,主要得益于对J&J MITEK的转移销售增长14% [47] - 关节修复与保护业务: - 国际市场持续增长,抵消了美国市场成熟产品销售下降 [34] 公司战略和发展方向及行业竞争 - 公司将重点聚焦在增长潜力最大的新产品,如Integrity、X-Twist和RevoMotion,以及高度差异化的HA和HA基再生技术 [28] - 公司正在采取措施降低支出,加速向盈利能力转型,预计2024年调整后EBITDA将增长超过75% [30][31] - 公司正在评估各种增加股东价值的机会,包括潜在出售,但目前更看重新聚焦战略的执行 [29] - 公司在OA疼痛管理和再生业务方面拥有核心优势,Cingal和Hyalofast有望成为未来重要的增长动力 [14][19] 管理层对经营环境和未来前景的评论 - 管理层对公司2023年的业绩表现感到满意,认为取得了关键里程碑,并对未来前景充满信心 [10] - 管理层表示,公司正在采取措施加快向盈利能力转型,预计2024年调整后EBITDA将大幅增长 [30][31] - 管理层对Integrity、X-Twist和RevoMotion等新产品的市场反馈和增长前景感到乐观 [16][24][26] - 管理层对Cingal和Hyalofast在美国市场的机遇充满信心,认为这些产品将成为未来重要的增长动力 [13][19] 问答环节重要的提问和回答 问题1 **Alex Hantman 提问** 询问裁员的具体影响范围 [66] **Cheryl Blanchard 回答** 主要影响R&D和营销等SG&A部门 [67] **Mike Levitz 回答** 约1000万美元的年度成本节约将在R&D和SG&A之间平均分配 [68] 问题2 **George Sellers 提问** 询问RevoMotion在季度内的贡献以及培训进展 [75][76] **Cheryl Blanchard 回答** 公司未单独披露各产品的贡献,而是进行整体培训。2023年共培训了约600名医生 [76][77] **Mike Levitz 回答** X-Twist、RevoMotion和Integrity等新产品是2024年增长的主要驱动力,而成熟产品的增长有限 [78][79][80] 问题3 **Mike Petusky 提问** 询问除新产品外,公司其他业务在2024年的表现预期 [87][90] **Mike Levitz 回答** 新产品是主要的增长动力,但成熟产品也会有一定贡献,公司正在平衡新老产品的增长 [88][89] **Cheryl Blanchard 回答** Integrity产品在有限市场发布后反响良好,公司正在根据反馈优化交付系统,计划于今年中期进行全面上市 [92][93][94]

业绩总结 - Anika Therapeutics, Inc. 2023年第四季度总收入为43.0百万美元，同比增长8%[6] - FY2023总收入为166.7百万美元，同比增长7%[8] - Anika Therapeutics, Inc. OA疼痛管理产品家族2023年第四季度收入为25072千美元，较2022年同期的22451千美元增长12%[4] 用户数据 - OA疼痛管理部门2023年收入为101.9百万美元，同比增长11%[8] 未来展望 - Anika在OA疼痛管理领域取得了记录年度业绩[9] 新产品和新技术研发 - 2023年第四季度非骨科收入为2.6百万美元，同比下降8%[6] 市场扩张和并购 - Anika Therapeutics, Inc. 2023年第四季度调整后EBITDA为5798千美元，较2022年同期的1375千美元大幅增长[2] 负面信息 - Anika Therapeutics, Inc. 2023年第四季度调整后毛利率为65%，较2022年同期的66%略有下降[1]

EXHIBIT 99.1 Anika Reports Fourth Quarter and Year-End 2023 Financial Results Revenue growth and adjusted EBITDA exceeded expectations in the fourth quarter and full year OA Pain Management achieved record annual revenues of $102 million, up 11% in 2023 Announces cost reduction initiatives providing annualized savings of approximately $10 million Anika positioned to generate adjusted EBITDA of $25 to $30 million in 2024, up over 75% at the midpoint, representing an adjusted EBITDA margin of at least 15% BED ...

BEDFORD, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that on March 1, 2024, Anika granted non-statutory stock options ("Options") covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.14, which equaled the closing price of common stock on the Nasdaq Global Select Market ("Closing Price") on the grant date, to one newly hired non-executive employee. ...